-
WFH publishes 3rd Edition of the Guidelines for the Management of Hemophilia
The World Federation of Hemophilia (WFH) has published the 3rd Edition of the Guidelines for the Management of Hemophilia, replacing the 2nd Edition published in 2012. The 158-page document...
FDA denies approval of Biomarin’s FVIII gene therapy
In a decision that surprised many, the U.S. Food and Drug Administration (FDA) last week denied approval of Biomarin’s FVIII gene therapy, branded Roctavian. The therapy has also been...
Management of comorbidities in bleeding disorders
Three decades of people with hemophilia unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, has again seen an increase in...
INNOVATORS
BUILDER
Believers
